{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:58:36Z","timestamp":1792047516804,"version":"4.4.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies suggest that plerixafor mobilization and apheresis in patients with sickle cell disease (SCD) is safe and can allow collection of sufficient CD34+ hematopoietic stem cell (HSC) collection for clinical gene therapy applications. However, the quantities of plerixafor-mobilized CD34+ cells vary between different SCD patients for unknown reasons. Twenty-three participants with SCD underwent plerixafor mobilization followed by apheresis, processing, and HSC enrichment under a phase 1 safety and efficacy study conducted at 2 institutions. Linear regression or Spearman's correlation test was used to assess the relationships between various hematologic and clinical parameters with total CD34+ cells\/kg collected. Median CD34+ cells\/kg after 2 or fewer mobilization and apheresis cycles was 4.0 \u00d7 106 (range, 1.5-12.0). Similar to what is observed generally, CD34+ yield correlated negatively with age (P &amp;lt; .001) and positively with baseline (P = .003) and preapheresis blood CD34+ cells\/\u00b5L (P &amp;lt; .001), and baseline white blood cell (P = .01) and platelet counts (P = .03). Uniquely for SCD, CD34+ cell yields correlated positively with the number of days hydroxyurea was held (for up to 5 weeks, P = .01) and negatively with markers of disease severity, including hospitalization frequency within the preceding year (P = .01) and the number of medications taken for chronic pain (P = .002). Unique SCD-specific technical challenges in apheresis were also associated with reduced CD34+ cell collection efficiency and purification. Here, we describe factors that impact plerixafor mobilization success in patients with SCD, confirming known factors as described in other populations in addition to reporting previously unknown disease specific factors in patients with SCD. This trial was registered at www.clinicaltrials.gov as #NCT03226691.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004232","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T20:27:06Z","timestamp":1620419226000},"page":"2403-2411","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-3879","authenticated-orcid":false,"given":"Alexis","family":"Leonard","sequence":"first","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch, NHLBI\/NIDDK, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-8991","authenticated-orcid":false,"given":"Naoya","family":"Uchida","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch, NHLBI\/NIDDK, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stroncek","sequence":"additional","affiliation":[{"name":"Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya R.","family":"Panch","sequence":"additional","affiliation":[{"name":"Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamille","family":"West","sequence":"additional","affiliation":[{"name":"Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoghan","family":"Molloy","sequence":"additional","affiliation":[{"name":"Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hauffe","sequence":"additional","affiliation":[{"name":"Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffani","family":"Taylor","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch, NHLBI\/NIDDK, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-7167","authenticated-orcid":false,"given":"Courtney","family":"Fitzhugh","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch, NHLBI\/NIDDK, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-7321","authenticated-orcid":false,"given":"Jane S.","family":"Hankins","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdar Q.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-6615","authenticated-orcid":false,"given":"Matthew","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch, NHLBI\/NIDDK, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-9439","authenticated-orcid":false,"given":"John F.","family":"Tisdale","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch, NHLBI\/NIDDK, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"6","key":"2021050615345115900_B1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med"},{"issue":"9","key":"2021050615345115900_B2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"2021050615345115900_B3","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2021050615345115900_B4","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood.V89.7.2233","article-title":"The biology and clinical uses of blood stem cells","volume":"89","author":"To","year":"1997","journal-title":"Blood"},{"issue":"9107","key":"2021050615345115900_B5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(05)60614-9","article-title":"Granulocytosis causing sickle-cell crisis","volume":"351","author":"Abboud","year":"1998","journal-title":"Lancet"},{"issue":"10","key":"2021050615345115900_B6","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1182\/blood.V97.10.3313","article-title":"Fatal sickle cell crisis after granulocyte colony-stimulating factor administration","volume":"97","author":"Adler","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2021050615345115900_B7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"issue":"19","key":"2021050615345115900_B8","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/bloodadvances.2018016725","article-title":"Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients","volume":"2","author":"Esrick","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"2021050615345115900_B9","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.3324\/haematol.2019.236182","article-title":"Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor","volume":"105","author":"Uchida","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2021050615345115900_B10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.2017.187047","article-title":"Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results","volume":"103","author":"Boulad","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"2021050615345115900_B11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3324\/haematol.2017.184788","article-title":"Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion","volume":"103","author":"Lagresle-Peyrou","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"2021050615345115900_B12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"issue":"3","key":"2021050615345115900_B13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-3542(97)00025-9","article-title":"Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin\/CXCR-4","volume":"35","author":"Schols","year":"1997","journal-title":"Antiviral Res"},{"issue":"1-3","key":"2021050615345115900_B14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(02)03143-5","article-title":"Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4","volume":"527","author":"Hatse","year":"2002","journal-title":"FEBS Lett"},{"issue":"3","key":"2021050615345115900_B15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.20110132","article-title":"The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in","volume":"208","author":"Ehninger","year":"2011","journal-title":"J Exp Med"},{"issue":"8","key":"2021050615345115900_B16","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20041385","article-title":"Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist","volume":"201","author":"Broxmeyer","year":"2005","journal-title":"J Exp Med"},{"issue":"6","key":"2021050615345115900_B17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2004.07.131","article-title":"Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin\u2019s lymphoma","volume":"22","author":"Devine","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021050615345115900_B18","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2003-02-0663","article-title":"Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist","volume":"102","author":"Liles","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2021050615345115900_B19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.15902","article-title":"Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery","volume":"186","author":"Leonard","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2021050615345115900_B20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/scd.2016.0230","article-title":"Gene therapy with hematopoietic stem cells: the diseased bone marrow\u2019s point of view","volume":"26","author":"Cavazzana","year":"2017","journal-title":"Stem Cells Dev"},{"issue":"19","key":"2021050615345115900_B21","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1182\/blood-2016-09-739722","article-title":"Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft","volume":"129","author":"Schroeder","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2021050615345115900_B22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/trf.15037","article-title":"The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study","volume":"59","author":"de Greef","year":"2019","journal-title":"Transfusion"},{"issue":"3","key":"2021050615345115900_B23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3324\/haematol.2016.147132","article-title":"Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial","volume":"102","author":"Pantin","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2021050615345115900_B24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1705431","article-title":"Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization","volume":"38","author":"Fu","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2021050615345115900_B25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.bmt.1704466","article-title":"Prediction of mobilisation failure in patients with non-Hodgkin\u2019s lymphoma","volume":"33","author":"Kuittinen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2021050615345115900_B26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705897","article-title":"Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis","volume":"41","author":"Jantunen","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2021050615345115900_B27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.22038","article-title":"Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization","volume":"86","author":"Basak","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"2021050615345115900_B28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","article-title":"Advances in stem cell mobilization","volume":"28","author":"Hopman","year":"2014","journal-title":"Blood Rev"},{"issue":"6","key":"2021050615345115900_B29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajh.21400","article-title":"Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma","volume":"84","author":"Hosing","year":"2009","journal-title":"Am J Hematol"},{"issue":"5","key":"2021050615345115900_B30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2141.2006.06223.x","article-title":"Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used","volume":"134","author":"Ings","year":"2006","journal-title":"Br J Haematol"},{"key":"2021050615345115900_B31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3389\/fimmu.2018.00845","article-title":"Peripheral blood stem cell mobilization in healthy donors by granulocyte colony-stimulating factor causes preferential mobilization of lymphocyte subsets","volume":"9","author":"Melve","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2021050615345115900_B32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. Rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2021050615345115900_B33","first-page":"40","article-title":"Cost of hospitalizations associated with sickle cell disease in the United States","volume":"112","author":"Davis","year":"1997","journal-title":"Public Health Rep"},{"issue":"5","key":"2021050615345115900_B34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/jhm.850","article-title":"Prediction of onset and course of high hospital utilization in sickle cell disease","volume":"6","author":"Carroll","year":"2011","journal-title":"J Hosp Med"},{"issue":"3","key":"2021050615345115900_B35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.10305","article-title":"Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients","volume":"72","author":"Houston-Yu","year":"2003","journal-title":"Am J Hematol"},{"issue":"5","key":"2021050615345115900_B36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.annemergmed.2008.07.050","article-title":"Comparisons of high versus low emergency department utilizers in sickle cell disease","volume":"53","author":"Aisiku","year":"2009","journal-title":"Ann Emerg Med"},{"issue":"1","key":"2021050615345115900_B37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ajh.20336","article-title":"Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance","volume":"79","author":"Ballas","year":"2005","journal-title":"Am J Hematol"},{"issue":"10","key":"2021050615345115900_B38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.21515","article-title":"The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization","volume":"84","author":"Carroll","year":"2009","journal-title":"Am J Hematol"},{"issue":"4","key":"2021050615345115900_B39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/AJP.0b013e3182579b87","article-title":"A preliminary study of psychiatric, familial, and medical characteristics of high-utilizing sickle cell disease patients","volume":"29","author":"Carroll","year":"2013","journal-title":"Clin J Pain"},{"issue":"7","key":"2021050615345115900_B40","first-page":"1109","article-title":"Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study","volume":"98","author":"Epstein","year":"2006","journal-title":"J Natl Med Assoc"},{"issue":"4","key":"2021050615345115900_B41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ajh.20485","article-title":"Medical care utilization and mortality in sickle cell disease: a population-based study","volume":"80","author":"Shankar","year":"2005","journal-title":"Am J Hematol"},{"issue":"3","key":"2021050615345115900_B42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.11124\/JBISRIR-2016-002983","article-title":"Factors influencing utilization of hospital services by adult sickle cell disease patients: a systematic review","volume":"15","author":"Benenson","year":"2017","journal-title":"JBI Database Syst Rev Implement Reports"},{"issue":"8","key":"2021050615345115900_B43","doi-asserted-by":"crossref","first-page":"e0133116","DOI":"10.1371\/journal.pone.0133116","article-title":"Elevated steady state WBC and platelet counts are associated with frequent emergency room use in adults with sickle cell anemia","volume":"10","author":"Curtis","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"2021050615345115900_B44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.bcmd.2005.06.014","article-title":"Collection of blood stem cells from patients with sickle cell anemia","volume":"35","author":"Richard","year":"2005","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"2021050615345115900_B45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/mt.2011.195","article-title":"Hematopoietic stem cell mobilization for gene therapy of adult patients with severe \u03b2-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects","volume":"20","author":"Yannaki","year":"2012","journal-title":"Mol Ther"},{"issue":"5","key":"2021050615345115900_B46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2021050615345115900_B47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2021050615345115900_B48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"2021050615345115900_B49","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.24562","article-title":"Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia","volume":"91","author":"Quinn","year":"2016","journal-title":"Am J Hematol"},{"issue":"17","key":"2021050615345115900_B50","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2021050615345115900_B51","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/humc.2017.029","article-title":"Bone marrow as a hematopoietic stem cell source for gene therapy in sickle cell disease: evidence from rhesus and SCD patients","volume":"28","author":"Uchida","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"2021050615345115900_B52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-142804","article-title":"Mgta-145, in combination with plerixafor in a phase 1 clinical trial, mobilizes large numbers of human hematopoietic stem cells and a graft with immunosuppressive effects for allogeneic transplant","volume":"136","author":"Goncalves","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/9\/2403\/1806878\/advancesadv2021004232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/9\/2403\/1806878\/advancesadv2021004232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:30:57Z","timestamp":1699011057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/9\/2403\/475877\/Disease-severity-impacts-plerixafor-mobilized-stem"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,5,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004232","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]}}}